2024
The effect of plerixafor on autologous stem cell mobilization, cell viability, and apheresis challenges
Puzo C, Li P, Tormey C, Siddon A. The effect of plerixafor on autologous stem cell mobilization, cell viability, and apheresis challenges. Lab Medicine 2024, 56: 187-194. PMID: 39303673, DOI: 10.1093/labmed/lmae080.Peer-Reviewed Original ResearchAutologous stem cell transplantationHematopoietic stem cellsMultiple myelomaG-CSFMobilization failureDiffuse large B-cell lymphomaAutologous stem cell mobilizationLarge B-cell lymphomaGranulocyte colony-stimulating factorAutologous stem cell transplant patientsEfficacy of plerixaforStem cell mobilizationB-cell lymphomaStem cell transplantationEffects of plerixaforRetrospective chart reviewColony-stimulating factorYale-New Haven HospitalCell viabilityMultiple risk factorsHodgkin lymphomaNon-HodgkinMobilization regimenCell transplantationPlerixaforOmission of 5-Fluorouracil Bolus From Multidrug Regimens for Advanced Gastrointestinal Cancers: A Multicenter Cohort Study.
Peng C, Saffo S, Oberstein P, Shusterman M, Thomas C, Becker D, Berlin J, Leichman L, Boursi B, Nagar A, Yu S. Omission of 5-Fluorouracil Bolus From Multidrug Regimens for Advanced Gastrointestinal Cancers: A Multicenter Cohort Study. Journal Of The National Comprehensive Cancer Network 2024, 22: 521-527. PMID: 39236754, DOI: 10.6004/jnccn.2024.7029.Peer-Reviewed Original ResearchMultidrug regimensFOLFIRINOX regimensAdvanced colorectalGastrointestinal cancerAssociated with decreased survivalGranulocyte colony-stimulating factorCompare survival outcomesGastrointestinal cancer treatmentBaseline clinical factorsKaplan-Meier analysisFirst-line FOLFOXMulticenter cohort studyColony-stimulating factorInverse probability of treatmentAdvanced gastrointestinal cancerTreatment selection biasProbability of treatmentHealth care savingsCox proportional hazardsOverall survivalEffective regimenIPTW analysisSurvival outcomesPancreatic cancerAssociated with reductionsThe protein disulfide isomerase A3 and osteopontin axis promotes influenza‐induced lung remodelling
Kumar A, Mark Z, Carbajal M, DeLima D, Chamberlain N, Walzer J, Ruban M, Chandrasekaran R, Daphtary N, Aliyeva M, Poynter M, Janssen‐Heininger Y, Bates J, Alcorn J, Britto C, Dela Cruz C, Jegga A, Anathy V. The protein disulfide isomerase A3 and osteopontin axis promotes influenza‐induced lung remodelling. British Journal Of Pharmacology 2024, 181: 4610-4627. PMID: 39118388, DOI: 10.1111/bph.16511.Peer-Reviewed Original ResearchProtein disulfide isomerase A3Secreted phosphoprotein 1Lung fibrosisLung remodelingFibrotic remodelingViral infectionAssociated with pulmonary fibrosisInfluenza-infected patientsMacrophage colony-stimulating factorFibrotic lung remodelingSPP1 expressionRespiratory viral infectionsImproved oxygen saturationColony-stimulating factorLung fibrotic remodelingDebilitating clinical sequelaeIAV infectionFibrotic sequelaeClinical sequelaeTherapeutic optionsPulmonary fibrosisRetrospective analysisNeutralizing antibodiesCell culture modelHealthy controlsRecruited atypical Ly6G+ macrophages license alveolar regeneration after lung injury
Ruscitti C, Abinet J, Maréchal P, Meunier M, de Meeûs C, Vanneste D, Janssen P, Dourcy M, Thiry M, Bureau F, Schneider C, Machiels B, Hidalgo A, Ginhoux F, Dewals B, Guiot J, Schleich F, Garigliany M, Bellahcène A, Radermecker C, Marichal T. Recruited atypical Ly6G+ macrophages license alveolar regeneration after lung injury. Science Immunology 2024, 9: eado1227-eado1227. PMID: 39093958, PMCID: PMC7616420, DOI: 10.1126/sciimmunol.ado1227.Peer-Reviewed Original ResearchConceptsLung injuryAlveolar regenerationGranulocyte-macrophage colony-stimulating factorColony-stimulating factorType 2 epithelial cellsAlveolar type 2 epithelial cellsPopulation of macrophagesModels of injuryImmune cellsSuspected pneumoniaA virusAlveolar damageEpithelial regenerationInterleukin-4Lung damageMacrophage subsetsReceptor signalingLungPerilesional areaRepair responseMacrophagesTherapeutic targetInjuryCellsAirborne pathogensStem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide(Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Real World Experience
Varga C, Robinson M, Ehsan H, Roberts D, Dicamillo S, Gupta V, Borden S, Bhutani M, Paul B, Atrash S, Ferreri C, Nooka A, Voorhees P, Joseph N. Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide(Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Real World Experience. Transplantation And Cellular Therapy 2024, 30: s377-s378. DOI: 10.1016/j.jtct.2023.12.528.Peer-Reviewed Original ResearchNewly diagnosed multiple myelomaLevine Cancer InstituteStem cell yieldNewly diagnosed multiple myeloma patientsStem cell collectionStem cell mobilizationInduction therapyG-CSFDose of G-CSFTransplant-eligible NDMM patientsCell mobilizationCycles of induction therapyCell collectionCancer InstituteCD34+ cells/kgMRD-negative statusMedian patient ageStem cell harvestWinship Cancer InstituteCD34+ cellsGrowth colony-stimulating factorColony-stimulating factorNDMM patientsGoal dosePatient ageSmall-molecule CBP/p300 histone acetyltransferase inhibition mobilizes leukocytes from the bone marrow via the endocrine stress response
Jaschke N, Breining D, Hofmann M, Pählig S, Baschant U, Oertel R, Traikov S, Grinenko T, Saettini F, Biondi A, Stylianou M, Bringmann H, Zhang C, Yoshida T, Weidner H, Poller W, Swirski F, Göbel A, Hofbauer L, Rauner M, Scheiermann C, Wang A, Rachner T. Small-molecule CBP/p300 histone acetyltransferase inhibition mobilizes leukocytes from the bone marrow via the endocrine stress response. Immunity 2024, 57: 364-378.e9. PMID: 38301651, PMCID: PMC10923082, DOI: 10.1016/j.immuni.2024.01.005.Peer-Reviewed Original ResearchConceptsCorticotropin-releasing hormone receptor 1Hypothalamus-pituitary-adrenal glandAdrenocorticotropic hormoneBone marrowGranulocyte colony-stimulating factorAugmented host defenseMobilization of leukocytesColony-stimulating factorHistone acetyltransferase inhibitionHormone receptor 1Leukemic transformationG-CSFNeutrophil mobilizationReceptor 1Leukocyte mobilizationLeukocyte distributionHistone acetyltransferaseLeukocyte compartmentNeuroendocrine loopHost defenseEndocrine stress responseLeukocytesMarrowBloodReversible inhibition
2022
Toll-like receptor 7 regulates cardiovascular diseases
Shafeghat M, Kazemian S, Aminorroaya A, Aryan Z, Rezaei N. Toll-like receptor 7 regulates cardiovascular diseases. International Immunopharmacology 2022, 113: 109390. PMID: 36330918, DOI: 10.1016/j.intimp.2022.109390.Peer-Reviewed Original ResearchConceptsTLR-7Toll-like receptorsIncreased risk of complete heart blockRisk of complete heart blockGranulocyte-macrophage colony-stimulating factorTLR-7 activationTLR-7 ligandsVascular smooth muscle cellsComplete heart blockImmune system's roleLeft ventricular remodelingColony-stimulating factorDamage-associated molecular patternsSmooth muscle cellsInnate immune receptorsPro-inflammatory natureRisk of thrombus formationHeart blockImmune cellsVentricular remodelingIncreased riskMuscle cellsAtherosclerotic plaque formationSingle-stranded ribonucleic acidViral infectionHuman neutrophil development and functionality are enabled in a humanized mouse model
Zheng Y, Sefik E, Astle J, Karatepe K, Öz HH, Solis AG, Jackson R, Luo HR, Bruscia EM, Halene S, Shan L, Flavell RA. Human neutrophil development and functionality are enabled in a humanized mouse model. Proceedings Of The National Academy Of Sciences Of The United States Of America 2022, 119: e2121077119. PMID: 36269862, PMCID: PMC9618085, DOI: 10.1073/pnas.2121077119.Peer-Reviewed Original ResearchConceptsHumanized mouse modelMouse modelHuman immune systemHuman neutrophilsImmune systemFunctional human immune systemGranulocyte colony-stimulating factorUnique mouse modelColony-stimulating factorHuman G-CSFMISTRG miceG-CSF receptor geneBacterial burdenInfectious challengeG-CSFNeutrophilsMiceNeutrophil developmentReceptor geneDiseaseMultiomic characterization of pancreatic cancer-associated macrophage polarization reveals deregulated metabolic programs driven by the GM-CSF–PI3K pathway
Boyer S, Lee H, Steele N, Zhang L, Sajjakulnukit P, Andren A, Ward M, Singh R, Basrur V, Zhang Y, Nesvizhskii A, di Magliano M, Halbrook C, Lyssiotis C. Multiomic characterization of pancreatic cancer-associated macrophage polarization reveals deregulated metabolic programs driven by the GM-CSF–PI3K pathway. ELife 2022, 11: e73796. PMID: 35156921, PMCID: PMC8843093, DOI: 10.7554/elife.73796.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCell Line, TumorCell Transformation, NeoplasticGene Expression ProfilingGranulocyte-Macrophage Colony-Stimulating FactorHumansMetabolic Networks and PathwaysMetabolomicsMiceMice, Inbred C57BLPancreatic NeoplasmsProteomicsSignal TransductionTranscription FactorsTumor-Associated MacrophagesConceptsTumor-educated macrophagesSingle-cell RNA sequencing datasetsCancer cellsMultiomics characterizationRNA sequencing datasetsTumor-associated macrophagesPI3K-Akt pathwayPI3K pathwayMetabolic programsSequencing datasetsGene expressionMetabolic crosstalkFunction of TAMsCell typesK pathwayGM-CSFGranulocyte-macrophage colony-stimulating factorTumor promotingModel systemEpithelial cellsPathwayColony-stimulating factorMetabolic signaturesMutant KrasMalignant epithelial cellsThe ASH-ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question
O’Brien S, Badawy SM, Rotz SJ, Shah MD, Makarski J, Bercovitz RS, Hogan MS, Luchtman-Jones L, Panepinto JA, Priola GM, Witmer CM, Wolfson JA, Yee M, Hicks LK. The ASH-ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question. Blood Advances 2022, 6: 679-685. PMID: 35072726, PMCID: PMC8791561, DOI: 10.1182/bloodadvances.2020003635.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHealth care providersAsymptomatic childrenHematologic testsFamily historyCare providersRed blood cell transfusionChoosing Wisely projectBlood cell transfusionPediatric Hematology/OncologyGranulocyte colony-stimulating factorChoosing Wisely campaignHistory of recurrentChoosing Wisely recommendationsIron deficiency anemiaPositive family historyHematology/oncologyQuality improvement initiativesAmerican SocietyColony-stimulating factorInternal Medicine FoundationAutoimmune neutropeniaActive bleedingCell transfusionPlatelet transfusionsTask Force
2021
Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated following Allogeneic Transplantation in Patients with Sickle Cell Disease
Shah NC, Bhoopatiraju S, Abraham A, Anderson E, Andreansky M, Bhatia M, Chaudhury S, Cuvelier GDE, Godder K, Grimley M, Hale G, Kamani N, Jacobsohn D, Ngwube A, Gilman AL, Skiles J, Yu LC, Shenoy S. Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated following Allogeneic Transplantation in Patients with Sickle Cell Disease. Transplantation And Cellular Therapy 2021, 28: 174.e1-174.e5. PMID: 34958973, DOI: 10.1016/j.jtct.2021.12.016.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantationSickle cell diseaseNeutrophil recoveryG-CSFCell diseaseReduced-intensity conditioning hematopoietic stem cell transplantationReversible posterior leukoencephalopathy syndromeCalcineurin inhibitor therapyHemoglobin S levelPosterior leukoencephalopathy syndromeLife-threatening complicationsG-CSF useGranulocyte-colony stimulating factorStem cell infusionStem cell transplantationGranulocyte colony-stimulating factorG-CSF initiationAvailable stem cell sourceStem cell sourceColony-stimulating factorLeukoencephalopathy syndromeSickle vasculopathyHSCT recipientsNeutrophil engraftmentPlatelet engraftmentThe ASH‐ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question
O'Brien SH, Badawy SM, Rotz SJ, Shah MD, Makarski J, Bercovitz RS, Hogan M, Luchtman‐Jones L, Panepinto JA, Priola GM, Witmer CM, Wolfson JA, Yee M, Hicks LK. The ASH‐ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question. Pediatric Blood & Cancer 2021, 68: e28967. PMID: 34047047, DOI: 10.1002/pbc.28967.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHealth care providersAsymptomatic childrenHematologic testsFamily historyCare providersRed blood cell transfusionChoosing Wisely projectProphylaxis of childrenBlood cell transfusionPediatric Hematology/OncologyGranulocyte colony-stimulating factorChoosing Wisely campaignHistory of recurrentChoosing Wisely recommendationsIron deficiency anemiaPositive family historyHematology/oncologyQuality improvement initiativesAmerican SocietyColony-stimulating factorInternal Medicine FoundationAutoimmune neutropeniaActive bleedingCell transfusionPlatelet transfusionsCirculating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma
Chehrazi-Raffle A, Meza L, Alcantara M, Dizman N, Bergerot P, Salgia N, Hsu J, Ruel N, Salgia S, Malhotra J, Karczewska E, Kortylewski M, Pal S. Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma. Journal For ImmunoTherapy Of Cancer 2021, 9: e002009. PMID: 33688021, PMCID: PMC7944971, DOI: 10.1136/jitc-2020-002009.Peer-Reviewed Original ResearchConceptsVascular endothelial growth factor tyrosine kinase inhibitorMetastatic renal cell carcinomaRenal cell carcinomaImmune checkpoint inhibitorsColony-stimulating factorClinical benefitPlasma cytokinesSystemic therapyCell carcinomaInterleukin-6Prospective correlative studyLines of therapyLow pretreatment levelsGranulocyte colony-stimulating factorGranulocyte-macrophage colony-stimulating factorRCC histologic subtypesMacrophage colony-stimulating factorICI armsICI therapyStable diseaseCheckpoint inhibitorsClinical responsePartial responseComplete responseImmunologic profileA neutrophil activation signature predicts critical illness and mortality in COVID-19
Meizlish ML, Pine AB, Bishai JD, Goshua G, Nadelmann ER, Simonov M, Chang CH, Zhang H, Shallow M, Bahel P, Owusu K, Yamamoto Y, Arora T, Atri DS, Patel A, Gbyli R, Kwan J, Won CH, Dela Cruz C, Price C, Koff J, King BA, Rinder HM, Wilson FP, Hwa J, Halene S, Damsky W, van Dijk D, Lee AI, Chun HJ. A neutrophil activation signature predicts critical illness and mortality in COVID-19. Blood Advances 2021, 5: 1164-1177. PMID: 33635335, PMCID: PMC7908851, DOI: 10.1182/bloodadvances.2020003568.Peer-Reviewed Original ResearchConceptsCritical illnessHealth system databaseNeutrophil activationCOVID-19Neutrophil activation signatureSevere COVID-19Intensive care unitGranulocyte colony-stimulating factorHigh mortality rateColony-stimulating factorSystem databaseHepatocyte growth factorClinical decompensationNeutrophil countImmune hyperactivationCare unitEarly elevationLipocalin-2Interleukin-8Longitudinal cohortClinical dataMortality ratePatientsIllnessActivation signature
2020
Aberrant expression of USF2 in refractory rheumatoid arthritis and its regulation of proinflammatory cytokines in Th17 cells
Hu D, Tjon E, Andersson K, Molica G, Pham M, Healy B, Murugaiyan G, Pochet N, Kuchroo V, Bokarewa M, Weiner H. Aberrant expression of USF2 in refractory rheumatoid arthritis and its regulation of proinflammatory cytokines in Th17 cells. Proceedings Of The National Academy Of Sciences Of The United States Of America 2020, 117: 30639-30648. PMID: 33203678, PMCID: PMC7720234, DOI: 10.1073/pnas.2007935117.Peer-Reviewed Original ResearchMeSH KeywordsAntirheumatic AgentsArthritis, RheumatoidBiomarkersCD4 AntigensCD4-Positive T-LymphocytesCytokinesGene ExpressionGene Expression ProfilingHumansInflammation MediatorsReceptors, CCR6Receptors, CXCR3RNA, Small InterferingSignal TransductionTh17 CellsTumor Necrosis Factor-alphaUpstream Stimulatory FactorsConceptsAnti-TNF therapyRefractory rheumatoid arthritisRheumatoid arthritisTh17 cellsT cellsProinflammatory cytokinesHigh-throughput gene expression analysisIL-17-producing Th17 cellsSignature genesDistinct gene expression profilesTranscription factor T-betProinflammatory cytokine IL-17ATranscription factor USF2Cytokines IL-17APathogenic Th17 cellsGene expression profilesGene expression analysisGranulocyte-macrophage colony-stimulating factorPotential therapeutic approachShort hairpin RNAColony-stimulating factorRA patientsIL-17ATh17 responsesExpression analysisGranulocyte Colony-Stimulating Factor Is Safe and Well Tolerated Following Allogeneic Transplantation in Patients with Sickle Cell Disease
Shah N, Bhoopatiraju S, Abraham A, Anderson E, Andreansky M, Bhatia M, Chaudhury S, Cuvelier G, Godder K, Grimley M, Hale G, Kamani N, Jacobsohn D, Ngwube A, Skiles J, Yu L, Shenoy S. Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated Following Allogeneic Transplantation in Patients with Sickle Cell Disease. Blood 2020, 136: 33. DOI: 10.1182/blood-2020-142696.Peer-Reviewed Original ResearchHematopoietic cell transplantationSickle cell diseaseAbsolute neutrophil countVaso-occlusive episodesG-CSF administrationNeutrophil recoveryG-CSFSCD patientsCell diseaseDay 100Unrelated donor hematopoietic cell transplantationDonor hematopoietic cell transplantationVaso-occlusive pain crisesHemoglobin S levelPrimary graft rejectionShort-course methotrexateAcute chest syndromeLife-threatening complicationsG-CSF useGranulocyte-colony stimulating factorGranulocyte colony-stimulating factorTranscranial Doppler velocitiesDifferent donor sourcesColony-stimulating factorSafety/toxicityConsiderations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic.
Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R, Curtin P, Geyer MB, Gojo I, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Lyman GH, Mukherjee S, Perez LE, Rosovsky RP, Roy V, Rugo HS, Vasu S, Wadleigh M, Westervelt P, Becker PS. Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic. Journal Of The National Comprehensive Cancer Network 2020, 19: 1-4. PMID: 32871558, PMCID: PMC9730290, DOI: 10.6004/jnccn.2020.7610.Peer-Reviewed Original ResearchErythrocyte-stimulating agentsHematopoietic growth factorsGrowth factorSARS-CoV-2 infectionPandemic SARS-CoV-2 infectionGranulocyte colony-stimulating factorColony-stimulating factorTreatment of cancerThrombopoietin mimeticsHigh riskSuch growth factorsStimulating agentsPatientsCancerCOVID-19 eraCOVID-19 pandemicInfectionHigh-risk environmentsNeutropeniaThrombocytopeniaMorbidityChemotherapyFactorsAnemiaGroupTransplant in Aplastic Anemia Using Combined Granulocyte Colony-Stimulating Factor Primed Blood and Bone Marrow Stem Cells: A Retrospective Analysis
Ali N, Butt A, Altaf B, Adil SN, Shaikh MU. Transplant in Aplastic Anemia Using Combined Granulocyte Colony-Stimulating Factor Primed Blood and Bone Marrow Stem Cells: A Retrospective Analysis. Transplantation Proceedings 2020, 53: 386-390. PMID: 32773285, DOI: 10.1016/j.transproceed.2020.06.035.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAnemia, AplasticChildChild, PreschoolFemaleGraft vs Host DiseaseGranulocyte Colony-Stimulating FactorHematopoietic Stem Cell MobilizationHematopoietic Stem Cell TransplantationHumansMaleMiddle AgedPeripheral Blood Stem Cell TransplantationPostoperative ComplicationsRetrospective StudiesTransplantation ConditioningYoung AdultConceptsBone marrow stem cellsAplastic anemiaMarrow stem cellsOverall survivalAntithymocyte globulinAllogeneic hematopoietic stem cell transplantHematopoietic stem cell transplantStem cellsStudy periodFrequency of GVHDHost disease (GVHD) prophylaxisStandard infection prophylaxisOnly curative optionBone marrow graftsStem cell transplantGranulocyte colony-stimulating factorColony-stimulating factorAga Khan UniversityAcute GVHDChronic GVHDConditioning regimenCurative optionTransplant outcomesAllogeneic transplantsConditioning regimensNeutropenic Enterocolitis: Clinical Features and Outcomes.
Abu-Sbeih H, Ali F, Chen E, Mallepally N, Luo W, Lu Y, Foo W, Qiao W, Okhuysen P, Adachi J, Hachem R, Altan M, Jenq R, Wang Y. Neutropenic Enterocolitis: Clinical Features and Outcomes. Diseases Of The Colon & Rectum 2020, 63: 381-388. PMID: 31842164, DOI: 10.1097/dcr.0000000000001548.Peer-Reviewed Original ResearchConceptsMD Anderson Cancer CenterNeutropenic enterocolitisGranulocyte colony-stimulating factorAnderson Cancer CenterCancer CenterColony-stimulating factorMucosal injuryClinical featuresSurvival rateTexas MD Anderson Cancer CenterConcomitant systemic infectionImmunosuppressive therapy useDuration of neutropeniaRetrospective cohort studyAbsolute neutrophil countCox regression analysisComprehensive cancer centerLower survival rateAbdominal symptomsEnterocolitis diagnosisEnterocolitis symptomsNeutropenia onsetPneumatosis intestinalisCohort studyColonic perforation
2019
Tubular GM-CSF Promotes Late MCP-1/CCR2-Mediated Fibrosis and Inflammation after Ischemia/Reperfusion Injury
Xu L, Sharkey D, Cantley LG. Tubular GM-CSF Promotes Late MCP-1/CCR2-Mediated Fibrosis and Inflammation after Ischemia/Reperfusion Injury. Journal Of The American Society Of Nephrology 2019, 30: 1825-1840. PMID: 31315923, PMCID: PMC6779361, DOI: 10.1681/asn.2019010068.Peer-Reviewed Original ResearchConceptsIschemia/reperfusion injuryWild-type miceTubular cellsTubular injuryReperfusion injuryImmune cellsKidney ischemia/reperfusion injuryUnilateral ischemia/reperfusion injuryMCP-1/CCR2Monocyte chemoattractant protein-1Initial kidney damageInjured tubular cellsKidney 14 daysKidney injury markersProgressive interstitial fibrosisProfibrotic growth factorsChemoattractant protein-1MCP-1 receptorGranulocyte-macrophage colony-stimulating factorRenal tubular cellsNumber of macrophagesTime of repairColony-stimulating factorCoculture of macrophagesMacrophages persist
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply